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Abstract
Background: Although the presence of seizures in dogs with meningoencephalitis of
unknown origin (MUO) has been associated with shorter survival times, data regard-
ing the prevalence and risk factors for postencephalitic epilepsy (PEE) is lacking.
Objectives: To describe the clinical features, prevalence, risk factors, and long-term
outcome of PEE in dogs with MUO.
Animals: Sixty-one dogs with presumptive diagnosis of MUO based on the clinico-
pathological and diagnostic imaging findings.
Methods: Retrospective study. Cases were identified by search of hospital medical
records for dogs with suspected or confirmed MUO. Medical records of dogs meeting
inclusion criteria were reviewed. Signalment, seizure history, clinicopathologic, and
magnetic resonance imaging (MRI) findings were recorded.
Results: Among 61 dogs at risk of PEE, 14 (23%) dogs developed PEE. Three of
14 dogs with PEE (21%) developed drug-resistant epilepsy. Dogs with PEE were
younger (P = .03; ORadjusted = 0.75; 95% confidence interval [CI], 0.58-0.98) and had
significantly shorter survival times (log-rank test P = .04) when compared to dogs that
did not develop epilepsy. The risk factors associated with the development of PEE
were the presence of acute symptomatic seizures (ASS; P = .04; ORadjusted = 4.76;
95% CI, 1.11-20.4) and MRI lesions in the hippocampus (P = .04; ORadjusted = 4.75;
95% CI, 1.07-21.0).
Conclusions and Clinical Importance: Dogs with MUO and seizures at the early stage
of the disease (ASS) seem to be at a higher risk of developing PEE.
Abbreviations: AED, antiepileptic drug; ASS, acute symptomatic seizures; CIs, confidence intervals; CNS, central nervous system; CSF, cerebrospinal fluid; GME, granulomatous
meningoencephalomyelitis; HR, hazard ratio; IQR, interquartile range; MRI, magnetic resonance imaging; MUO, meningoencephalitis of unknown origin; NLE, necrotizing leucoencephalitis; NME,
necrotizing meningoencephalitis; OR, odds ratio; OS, median overall survival time; PEE, postencephalitic epilepsy; SE, status epilepticus; T1W, T1-weighted; T2*, T2-weighted gradient recall
echo; T2-FLAIR, T2-weighted fluid attenuation inversion recovery; T2W, T2-weighted; WBC, white blood cell.
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1 | INTRODUCTION
Meningoencephalitis of unknown origin (MUO) is a common immune-
mediated, inflammatory central nervous system (CNS) disease in dogs.
The term MUO encompasses all clinically diagnosed cases of granulo-
matous meningoencephalomyelitis (GME), necrotizing meningoen-
cephalitis (NME), and necrotizing leucoencephalitis (NLE).1-3 In the
absence of histopathologic confirmation, presumptive diagnosis can
be established based on the combination of clinicopathological and
advanced imaging findings.1-4 Affected animals might display various
neurological signs including seizures. Furthermore, meningoencephali-
tis can present with seizures not only in the early stage of the disease
but can also lead to the later development of epilepsy.
Epilepsy is a complex disease characterized by recurrent
unprovoked epileptic seizures.5,6 Due to different underlying mecha-
nisms as well as prognosis, it is important to distinguish acute symp-
tomatic seizures (ASS) from late unprovoked seizures.7,8 ASS are
events occurring in close temporal association with an acute or an
active CNS insult, whereas unprovoked seizures occur in the absence
of a triggering condition or beyond the interval estimated for the
occurrence of ASS.9,10
In human medicine, the prevalence of postencephalitic epilepsy
(PEE) varies between studies, ranging from 6.1% to 46.5%11-16 and, a
substantial number of patients are refractory to antiepileptic drug
(AED) treatment.15-20
Acute symptomatic seizures are 1 of the major risk factors for the
development of PEE across different studies from human medi-
cine.11,15,16 Furthermore, certain MRI features such as T2-weighted
fluid attenuation inversion recovery (T2-FLAIR) abnormality of mesial
temporal structures, cortical and subcortical involvement, as well as
gadolinium contrast enhancement are predictive of PEE in patients
with infectious and autoimmune encephalitis.15,16
Although the presence of seizures in dogs with MUO has been
associated with shorter survival times,21-24 little is known regarding
predictors of seizures and PEE. Therefore, the aims of this study were
to report the clinical features, prevalence, risk factors, and long-term
outcome of PEE in dogs with MUO. We hypothesized that dogs with
ASS and MRI cortical involvement would be at a higher risk of devel-
oping PEE and that dogs with PEE would have shorter survival times.
2 | MATERIALS AND METHODS
2.1 | Case selection
The study was approved by the Research Ethics Committee of the
School of Veterinary Medicine of the University of Glasgow
(ref32a/17). The electronic database of the Small Animal Hospital of
the University of Glasgow was retrospectively searched between
2006 and 2017 for dogs with a final or presumptive diagnosis
of MUO.
The terms used for search were meningoencephalitis,
meningoencephalitis of unknown origin, MUO, granulomatous
meningoencephalomyelitis, GME, necrotizing meningoencephalitis,
NME, leucoencephalitis, NLE, encephalitis, and meningitis.
A presumptive diagnosis of MUO was based on guidelines pro-
posed by Granger et al.3 Dogs met inclusion criteria if they had
(1) complete medical history (2) suspected focal, multifocal, or diffuse
intracranial lesion based on the neurologic examination findings,
(3) evidence of single, multiple, or diffuse lesion on MRI performed at
presentation, (4) inflammatory cerebrospinal fluid (CSF) analysis per-
formed at presentation, and (5) dogs with GME, NME, NLE confirmed
by histopathologic evaluation only had to have available medical
records including history, ancillary tests results, and MRI. Dogs were
excluded if they (1) were diagnosed with eosinophilic
meningoencephalomyelitis, (2) were diagnosed with strictly spinal
meningomyelitis, (3) had only the optic form of MUO (4) or had infec-
tious meningoencephalitis, (5) had experienced a prior neurological
insult, (6) had a history of seizures, (7) had an underlying disease
which could result in reactive seizures, and (8) were lost to follow-up.
The minimum duration of follow-up was 12 months since the docu-
mented diagnosis of MUO or until death.
2.2 | Data collection
Data retrieved from the medical records was as follows: signalment,
history, and physical and neurologic examination findings. The pres-
ence or absence of seizures before diagnosis and within the first week
of diagnosis, seizure type (generalized or focal), frequency, and sever-
ity of seizures (isolated seizures, cluster seizures, status epilepticus
[SE], and refractory SE) were recorded. Seizures were characterized
mainly based on the medical history, owners' descriptions of the
events, and where available based on the postencephalitic question-
naire. Results of CBC, biochemistry profile, serum antibody titers
against Neospora caninum and Toxoplasma gondii, as well as CSF analy-
sis results and MRI findings, were evaluated. Cerebrospinal fluid anal-
ysis was considered normal if white blood cell (WBC) count was ≤5
cells/μL. Pleocytosis was classified as mild, if WBC count was greater
than reference ranges but less than 25 cells/μL, as moderate if WBC
count was between 26 and 100 cells/μL, and as marked severe if
WBC count was higher than 100 cells/μL. Protein concentration for
cisternal and lumbar CSF collection was considered normal for less
than 25 mg/dL and less than 35 mg/dL, respectively.25 All MRI studies
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were performed using a 1.5 Tesla system (Gyroscan ACS NT, Philips
Medical System, Eindhoven, The Netherlands or Magnetom, Siemens,
Camberley, United Kingdom) and included a minimum of sagittal,
transverse, and dorsal T2-weighted (T2W) images and transverse
T1-weighted (T1W) images of the entire brain. The T1W images were
acquired before and after paramagnetic contrast administration
(0.1 mmol/kg of gadopentetate dimeglumine, Magnevist; Bayer
HealthCare Pharmaceuticals, United Kingdom). Most of these studies
also included T2-FLAIR images and T2* gradient recall echo images.
All sequences were reviewed on an open-source PACS Workstation
DICOM viewer (Osirix Imaging Software, v 3.9.2, Pixmeo, Geneva,
Switzerland) by a board-certified neurologist who was blinded to the
PEE status. The anatomical regions for lesion location on MRI were as
follows: cerebrum (frontal, piriform, parietal, temporal, and occipital
lobes), olfactory bulb, hippocampus, thalamus, midbrain, cerebellum,
pons, medulla oblongata, spinal cord, and meninges. Changes in hippo-
campus were subjectively divided into postictal or lesion-related.
Bilateral, evenly and diffusely distributed symmetrical and non-con-
trast-enhancing changes were classified as postictal. The presence of
concomitant postictal changes in piriform lobes and cingulate gyri,
with the same MRI signal characteristics of hippocampus, was used to
support the classification of hippocampal changes as postictal.26,27 If
the hippocampus was involved in the borders of an ipsilateral lesion, it
was considered to be lesion-related. Lesions were described as focal,
multifocal, or diffuse and unilateral or bilateral. Margins were classi-
fied as well- or ill-defined. Distribution within white and gray matter,
cortical involvement, and the presence of T2-FLAIR perilesional
edema were assessed. Gadolinium contrast enhancement was
described as parenchymal, meningeal, or both. The degree of contrast
enhancement was subjectively classified as mild, moderate, and
severe. The presence or absence of mass effect, loss of cerebral sulci,
and the presence and type of brain herniation (foramen magnum or
caudal transtentorial) were recorded.
Dogs were divided into 2 groups, those with ASS and those with-
out ASS. All cases were followed up until death or for at least
12 months since the diagnosis of MUO. At follow-up, information
regarding the presence of seizures, seizure type, and the use of AED
was gathered from hospital medical records alone, from medical records
requested from referring veterinarian alone, or both hospital and refer-
ring veterinarian records, and if available from the owner. Both the vet-
erinary surgeon and the owner were contacted by telephone, email, or
by both. If available, additional data were obtained using a PEE ques-
tionnaire (enclosed in Appendix S1), which was posted to all owners.
The type and duration of treatment, the presence of a relapse, survival
times, and the cause of death were also recorded.
2.3 | Study definitions
Acute symptomatic seizures were defined as seizures preceding or
occurring within 1 week of documented diagnosis of MUO. Seizures
associated with relapse of MUO and occurring before or after 7 days
of relapse of MUO were classified as reappearing symptomatic
seizures. In the absence of diagnostic imaging studies, CSF analysis, or
both diagnostic tests, the relapse of MUO was diagnosed based on
the recurrence of previously described neurological deficits or devel-
opment of new signs of neurological disease.
Late unprovoked seizures were defined as seizures occurring
1 week after documented diagnosis of MUO and not associated with
a relapse of MUO.9,10,28 Postencephalitic epilepsy (PEE) was defined
as recurrent unprovoked seizures.5,6,29 Drug-resistant epilepsy was
defined as the persistence of uncontrolled seizures despite ≥2 appro-
priate AEDs at last follow-up.30,31 Cluster seizures were defined as
2 or more seizures within 24-hour period. Status epilepticus was
defined as greater than 5 minutes of continuous seizure activity or
2 or more seizures between which there is incomplete recovery of
consciousness.6 Status epilepticus was considered refractory if it
failed to respond to the first- and second-line treatments.32
2.4 | Statistical methods
Numerical variables were presented as a median and interquartile
range (IQR), and categorical variables were presented as a count and
percentage in a group. Confidence intervals (CIs) for proportions were
calculated using Wilsons's score method.
Risk factors for the occurrence of ASS and PEE were first identi-
fied using the Pearson's chi-square test or Fisher exact test if the
expected count was in 2-by-2 contingency table and was below
5 (dichotomous variables). A Mann-Whitney U test was used for
numerical variables or ordinal categorical variables with more than
2 categories. Factors for which P-value was below 0.1 were entered
into the multivariable logistic regression model (as dummy variables if
included more than 2 categories) according to the backward stepwise
procedure. Crude odds ratios (OR) and adjusted odds ratios
(ORadjusted) with 95% CIs were presented to describe the result of the
univariable and multivariable analysis, respectively. Goodness-of-fit of
the logistic regression model was assessed using Nagelkerke's
pseudo-R2 and Hosmer-Lemeshow test.
Prognostic factors of the median overall survival time (OS) in the
course of MUO were first identified using the Mantel-Cox log rank
test (dichotomous variables) or the univariable Cox proportional-
hazard model (continuous variables). Factors for which P-value was
below 0.1 were introduced in the multivariable Cox proportional haz-
ard model according to the backward stepwise procedure. In the OS
analysis, dogs were censored if they died from causes unrelated to
MUO or were still alive at the end of the observation period. Crude
hazard ratios (HR) and adjusted hazard ratios (HRadjusted) with 95% CIs
were presented to describe the result of the univariable and multivari-
able analysis, respectively. The OS of dogs in different groups were
presented using the Kaplan-Meier plots.
All statistical tests were 2-tailed, and a significance level (α) of
0.05 was assumed in all statistical tests except for univariable risk and
survival analyses in which α was 0.1.
Statistical analysis was performed in TIBCO Statistica 13.3.0
(TIBCO Software Inc., Palo Alto, California).
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3 | RESULTS
3.1 | Description of study population
One hundred eighty-eight cases with suspected meningoencephali-
tis were identified in the initial search. Of those 75 fulfilled
inclusion criteria (Figure 1), 40 were females (53%) and 35 were
males (47%), aged from 7 months to 13 years with a median of
4 years (IQR, 1.6-6.8 years). Twenty-three of 40 (57%) females and
19 of 35 (54%) males were neutered. Body weight ranged from
1.9 to 37.1 kg with a median of 9 kg (IQR, 6.6-19.2 kg). Sixty-one
dogs survived 1 week after diagnosis of MUO and were included
F IGURE 1 Flowchart of the case selection in the study. ASS, acute symptomatic seizures; CSF, cerebrospinal fluid; ICP, intracranial pressure;
MRI, magnetic resonance imaging; MUO, meningoencephalitis of unknown origin; PEE, postencephalitic epilepsy; WBC, white blood cell
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in the analysis of the risk factors for the development of PEE
(Figure 1).
Breeds presented included Lhasa Apso (6), Labrador (6), Pug (6),
Maltese Terrier (6), crossbreeds (6), Bichon Frise (5), Cocker Spaniel (4),
Chihuahua (3), West Highland White Terrier (3), Yorkshire Terrier (3),
Jack Russell Terrier (3), Shih Tzu (3), French Bulldog (2), Boston Terrier
(2), Border Collie (1), Border Terrier (1), Cairn Terrier (1), Doberman (1),
English Spaniel (1), German Shepherd (1), Greyhound (1), Hungarian
Vizsla (1), Lurcher (1), Miniature Pinscher (1), Papillon (1), Polish Low-
land Sheepdog (1), Golden Retriever (1), Shar-Pei (1), Shetland
Sheepdog (1), Staffordshire Terrier (1), and Weimaraner (1). Histopatho-
logical diagnosis was available for 6 dogs. Four dogs had GME
and 2 NME.
3.2 | Clinical presentation and ASS
Thirty-eight (51%) dogs were presented with ASS and 37 (49%) with-
out seizures (Figure 1). Dogs with ASS were significantly younger than
dogs without seizures (P = .02). The median age of dogs with ASS was
TABLE 1 Neurological examination findings in dogs with and without acute symptomatic seizures (ASS)
Neurological examination
findings
Total number of cases Number of cases with ASS Number of cases without ASS P-value (chi-square
or Fisher exact test)n = 75, n (%) n = 38, n (%) n = 37, n (%)
Obtundation 40 (53) 26 (68) 14 (38) .007a
Stupor 2 (3) 1 (3) 1 (3)
Abnormal gait 42 (56) 9 (24) 33 (89) .46
Circling 18 (24) 8 (21) 10 (27) .46
Ataxia 33 (44) 16 (42) 17 (46) .46
Paresis/plegia 13 (17) 6 (16) 7 (19) .46
Abnormal posture 32 (43) 14 (37) 18 (49) .42
Abnormal postural reactions 52 (69) 26 (68) 26 (70) .80
Cranial nerve deficits 53 (71) 28 (74) 25 (67) .43
Abnormal spinal reflexes 4 (5) 2 (5) 2 (5) .99
Head, neck, or back pain 13 (17) 5 (13) 8 (22) .49
aP values were calculated for dogs that presented either obtunded or stuporous.
TABLE 2 Correlation between acute symptomatic seizures (ASS) and magnetic resonance imaging (MRI) findings based on the univariable
analysis of categorical risk factors of ASS
Hypothesized MRI risk factor Category
n (%) of dogs with
ASS among dogs of
a particular category
P-value (chi-square
of Fisher exact test)
Transtentorial brain herniation Yes 9/10 (90.0) .004
No 29/65 (44.6)
Parietal lobe lesion Yes 21/30 (70.0) .006
No 17/45 (37.8)
Cortical involvement Yes 30/49 (61.2) .01
No 8/26 (30.8)
Temporal lobe lesion Yes 14/19 (73.7) .02
No 24/56 (42.9)
Meningeal contrast enhancement Marked 4/8 (50.0) .02
Moderate 9/15 (60.0)
Mild 24/37 (64.9)
No 1/15 (6.7)
T2-FLAIR perilesional edema Yes 35/62 (56.4) .02
No 3/13 (23.1)
Note. Only variables with P < .05 are presented in the table.
Abbreviation: FLAIR, fluid attenuation inversion recovery.
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3 years (IQR, 1.2-5.3) and 5 years for dogs without seizures (IQR
2.6-7.0). No significant difference was evident in sex (P = .42).
Neurological examination findings are presented in Table 1. Dogs
with ASS were more frequently presented obtunded or stuporous
(P = .007). Of those with ASS, 10 (26%) were presented with general-
ized seizures, 8 (21%) with focal seizures, 16 (42%) with both general-
ized and focal seizures, and the type of seizures was not specified for
4 (10%) cases. Eight (21.0%) dogs experienced isolated seizures,
27 (71%) had cluster seizures, and 7 (18%) cluster seizures which
progressed to SE. Four (10%) dogs developed refractory SE. The sei-
zure frequency and severity were insufficiently characterized for
3 (8%) cases. Twenty-seven owners responded to the PEE question-
naire. Among responders, 14 dogs were presented with ASS, 13 with-
out seizures, and 6 developed PEE.
Five of the 37 (13%) dogs that presented without ASS developed
seizures at a later stage. Three of these dogs presented seizures as a
sign of MUO relapse (25, 31, and 71 weeks after initial diagnosis,
respectively) and the remaining 2 did seizure while hospitalized for
the initial event at days 8 and 10, respectively. Statistically significant
differences in MRI findings between dogs with ASS and dogs without
seizures included MRI cortical involvement (P = .01), caudal trans-
tentorial brain herniation (P = .004), meningeal contrast enhancement
(P = .02), and the presence of T2-FLAIR perilesional edema (P = .02)
(Table 2). All variables are presented in Table 2A and B in Appen-
dix S1.
3.3 | Clinical presentation and risk factors for PEE
Among 61 dogs, which survived the first week, 14 (23%) developed
PEE (Figure 1). Similarly, to dogs with ASS, dogs with PEE were youn-
ger than dogs without PEE (P = .03). The median age of dogs with PEE
was 2.5 years (IQR, 1.5-4.3 years) and 5 years (IQR, 1.6-7.0 years) for
dogs without PEE.
Among dogs with PEE 11 (79%) presented with ASS, majority of
dogs, 8 of 11 (73%), with PEE in the acute phase experienced cluster
seizures, in which 2 dogs progressed to SE. Only 2 dogs (19%) were
presented with a single seizure episode, and the seizure frequency
was not specified for 1 case (9%).
Among them, 2 dogs experienced focal seizures (18%), 4 general-
ized (36%), and 3 (27%) both types of seizures. The information
regarding seizure type was not available for 2 dogs (18%). The
remaining 3 dogs with PEE which developed seizures at later stage of
MUO experienced clusters seizures. One dog had only generalized
and 2 dogs both generalized and focal seizures.
The variables significantly linked to the risk of PEE development
are presented in Table 3. All variables included in the univariable anal-
ysis are presented in Appendix S1. In the multivariable analysis, the
factors associated with PEE were ASS (P = .04; ORadjusted = 4.76; 95%
CI, 1.11-20.4) and hippocampal lesion on MRI (P = .04);
ORadjusted = 4.75; 95% CI, 1.07-21.0). Examples of MRI hippocampal
lesions are presented in Figure 2 and cortical lesions in Figure 3.
3.4 | MUO treatment
The majority of dogs received treatment with cytosine arabinoside
and prednisolone. In the group of dogs with ASS, 32 (84%) were
treated with cytosine arabinoside and prednisolone and 6 (16%) with
corticosteroids only. In the group of dogs without ASS, 29 (78.3%)
received cytosine arabinoside and prednisolone, 7 (19%) had cortico-
steroids only, and 1 (3%) died before the treatment was initiated.
Thirteen (93%) of 14 dogs which developed PEE received treat-
ment with cytosine arabinoside and prednisolone and 1 (7%) had
TABLE 3 Variables significantly related to the risk of development of postencephalitic epilepsy (PEE) in the univariable analysis
Hypothesized risk factor Category
n (%) of dogs with
PEE among dog of a
particular category
Chi-square test or
Mann-Whitney
U P-value OR (95% CI)
Age .03 0.75 (0.58-0.98)
Seizure activity
Acute symptomatic seizures Yes 11/29 (37.9) .007 5.91 (1.45-24.1)
No 3/32 (9.4)
MRI
MRI frontal lobe lesion Yes 11/33 (33.3) .03 4.17 (1.03-16.9)
No 3/28 (10.7)
MRI temporal lobe lesion Yes 7/14 (50.0) .01 5.71 (1.53-21.4)
No 7/47 (14.9)
MRI hippocampal lesion Yes 6/11 (54.5) .01 6.30 (1.54-25.7)
No 8/50 (16.0)
Note. Only variables with P < .05 are presented in the table.
Abbreviations: CI, confidence interval; MRI, magnetic resonance imaging; OR, odds ratio.
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corticosteroids only. Treatment with corticosteroids only was not pre-
dictive of PEE (P = .66).
In each group of dogs regardless of the presence or absence of
ASS, 12 dogs had a relapse of MUO. In the ASS group, 8 dogs had sei-
zures as a sign of a relapse of MUO and 3 of them had PEE.
In the non-ASS group, 3 cases experienced seizures as a sign of
a relapse of MUO and 2 of them had PEE. The first dog with PEE
and relapse with seizures experienced first seizure 11 days after
diagnosis and a relapse of MUO with seizures 500 days after the
diagnosis. The second dog experienced the first relapse 175 days
after the diagnosis and the first single seizure 17 days after the first
relapse of MUO. This dog had a second relapse of MUO manifested
with seizures 656 days after the diagnosis of MUO. One dog with
PEE had a relapse of MUO without seizures. Overall, 5 cases with
PEE experienced a relapse.
3.5 | Antiepileptic treatment
Patterns of AED use in dogs with ASS and PEE at discharge after hos-
pitalization for the initial event and at 12-month follow-up are pres-
ented in Table 4. The choice of AED was at the discretion of the
clinician in charge of the case or referring veterinarian.
At the time of writing this report, 6 dogs with ASS were still alive
and did not experience any further seizures. Three of these dogs con-
tinued treatment with AED. Two dogs stopped phenobarbital after
6 and 12 months. One dog discontinued levetiracetam 12 months
after diagnosis of MUO.
One dog with PEE did not receive any AED at the time of dis-
charge as it did not initially present with seizures. Despite the devel-
opment of PEE, this dog never received AED treatment. At the last
follow-up, 3 of 14 (21%) cases with PEE developed drug-resistant epi-
lepsy. Two dogs were treated with phenobarbital, levetiracetam, and
potassium bromide and 1 dog with phenobarbital, gabapentin, and
potassium bromide. The later became resistant to AED 3 years after
the diagnosis.
3.6 | Outcome
Median overall survival time for all dogs in our study regardless of the
presence or absence of seizures was 103 weeks (IQR, 3-429 weeks)
(Figure 4). One-week survival rate was 81.3% (95% CI, 71.1%-88.5%)
and the 1-year survival rate was 59% (95% CI. 47.4%-69.1%). Forty of
75 (53%) dogs died due to reasons related to MUO. Seven dogs (9%)
died of other reasons and 28 (37%) were alive at the time of the last
F IGURE 2 Transverse magnetic resonance T2WI (A), fluid attenuation inversion recovery (B), T1WI (C), T1WI-gad (D) of the brain of a dog
with postencephalitic epilepsy with a lesion affecting the left hippocampus (white arrow). The images were obtained at the times of diagnosis of
meningoencephalitis of unknown origin. T1WI, T1-weighted images; T2WI, T2-weighted images
F IGURE 3 Transverse magnetic resonance images T2WI (A), fluid attenuation inversion recovery (B), T1WI (C), T1WI-gad (D) of the brain of a
dog with postencephalitic epilepsy with a lesion affecting the cerebral cortex (white arrow). The images were obtained at the time of diagnosis of
meningoencephalitis of unknown origin. T1WI, T1-weighted images; T2WI, T2-weighted images
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follow-up. The duration of the long-term follow-up ranged from 52 to
439 weeks. In the multivariable analysis of the risk factors of death in
the course of MUO, only caudal transtentorial brain herniation
(P = .004; HRadjusted = 2.95; 95% CI, 1.41-6.15) remained significant.
Neither the presence of acute nor late seizures was related to the
higher risk of death. The treatment with corticosteroids only was not
linked to death in the course of MUO. The variables significantly
linked to death in the course of MUO are presented in the Table 5. All
variables included in the univariable analysis are presented in Appen-
dix S1. There was no statistically significant difference in the OS
between dogs with ASS and without seizures (Figure 5).
The analysis of OS in dogs at the risk of developing PEE included
61 dogs, which survived the first week following diagnosis. There
were 14 dogs with PEE (23%) and 47 (77%) without PEE. Dogs with
PEE had significantly shorter OS than dogs without PEE (P = .04).
Median overall survival time of dogs with PEE was 16 months (95%
CI, 4-28 months); the OS of dogs without PEE could not be
established as >50% of dogs survived till the end of the observation
period (Figure 6).
TABLE 4 Number of dogs receiving individual treatment with antiepileptic drug (AED), in dogs with acute symptomatic seizures (ASS) and
postencephalitic epilepsy (PEE) at discharge and at 12-month follow-up
ASS PEE
n = 38, n (%) n = 14, n (%)
Discharge 12-month Discharge 12-month
No AED 3 (10) 5 (26) 1 (7) 1 (7)
Phenobarbital 16 (61) 8 (57) 9 (64) 3 (33)
Levetiracetam 6 (23) 4 (28) 2 (14) 1 (11)
Phenobarbital and levetiracetam 4 (15) 1 (7) 1 (7) 2 (22)
Phenobarbital and potassium bromide 0 (0) 1 (7) 0 (0) 1 (11)
Phenobarbital, levetiracetam, and potassium bromide 0 (0) 0 (0) 0 (0) 1 (11)
F IGURE 4 Kaplan-Meier curve used to
determine the median overall survival time in all
dogs with meningoencephalitis of unknown origin
TABLE 5 The variables significantly linked with death in the
course of the disease in the univariable analysis
Hypothesized risk
factor
Univariable Cox
proportional hazard model
P-value
HR
(95% CI)
MRI loss of cerebral
sulci
.03 2.11
(1.07-4.16)
MRI brain herniation .04 1.94
(1.03-3.67)
MRI transtentorial brain
herniation
.002 3.11
(1.49-6.47)
Marked/moderate
meningeal contrast
enhancement
.03 2.01
(1.06-3.80)
Note. Only variables with P < .05 are presented in the table.
Abbreviations: CI, confidence interval; HR, hazard ratio; MRI, magnetic
resonance imaging.
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4 | DISCUSSION
The present study assessed the prevalence, risk factors, and long-term
outcome of PEE in dogs with MUO. Acute symptomatic seizures were
present in 51% of dogs with MUO and 23% developed recurrent
unprovoked seizures consistent with PEE. Of these, 21% developed
drug-resistant epilepsy. The presence of ASS and hippocampal lesions
on MRI was identified as predictors of PEE. Dogs with PEE were
younger and had significantly shorter survival times when compared
to dogs without PEE.
The prevalence of ASS in dogs with MUO in this report was 50%,
which is higher than in previously published studies, in which it ranged
from 23% to 37.5%.21,22 Similar variations between studies have been
reported in human medicine and could be due to differences in inclu-
sion criteria.11-16 Interestingly, the presence of ASS was a major risk
factor for PEE in this study. This finding is in agreement with previous
studies in humans in which patients with seizures in the acute phase
of encephalitis were much more likely to develop seizures in long-
term follow-up compared to patients without seizures.11,15,16
In human medicine, focal seizures are associated with seizure
recurrence not only in PEE but also in other types of epilepsies.15,16,33
In this study, 42% of dogs experienced both generalized and focal sei-
zures and 21% had only focal seizures. The type of seizures was not
associated with the development of PEE. However, seizure
F IGURE 5 Kaplan-Meier estimates of the
survival time for dogs with meningoencephalitis of
unknown origin. Dogs were assigned into
2 groups based on the presence (red line) or
absence (green line) of acute symptomatic
seizures. There was no significant difference
between groups (P = .40). PEE, postencephalitic
epilepsy
F IGURE 6 Kaplan-Meier estimates of the
survival time for dogs with meningoencephalitis of
unknown origin. Dogs were assigned into
2 groups based on the presence (red line) or
absence (green line) of postencephalitic epilepsy.
Survival time was significantly different between
groups (P = .04). ASS, acute symptomatic seizures
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classification was often based on the owner's description of the
events; therefore, some focal seizures could have remained
undetected.
The present study showed that the proportion of dogs with ASS
and PEE was higher among young individuals. Young age was also
reported as 1 of the predictors of seizures in viral or nonspecific enceph-
alitis in human studies.34 These results are in contrast to data obtained
from studies on animal models, where older rats were found more sus-
ceptible to seizure induction than their younger counterparts.35,36
In a previous study of Pugs with NME, all dogs presented with
seizures.37 Unfortunately, due to the low number of cases with a con-
firmed histopathological diagnosis in the present study, it was not
possible to evaluate the effect of type of inflammatory CNS disease
(NME versus GME) on PEE. The cause of encephalitis remains
unexplained in 20%-60% of human cases.38-40 However, the etiology
of encephalitis plays an important role in determining the prevalence
of seizures and subsequent epilepsy. In a recent study on drug-
resistant PEE in children, herpes virus encephalitis and encephalitis of
unknown etiology were the most common causes, with a prevalence
of drug-resistant epilepsy of 33% and 20%, respectively.15 In a study
focused on the adult population, the prevalence of PEE among
patients with autoimmune encephalitis reached 46.5% and with infec-
tious encephalitis 34.9%.16
The only imaging predictive factor of PEE in dogs in this study, which
remained significant on multivariate analysis, was the presence of lesions
affecting the hippocampus. This finding is similar to those of a recent
study on childhood drug-resistant PEE.15 Although the presence of brain
abnormalities on MRI following a single seizure or SE is considered as the
origin of epilepsy,41 certain MRI changes might be related to seizures and
difficult to distinguish from the primary inflammatory process. Due to the
retrospective nature of our study, subsequent MRI could not be obtained
to compare with the baseline images and some of the changes described
as lesion related could have represented postictal changes.
In this study, we classified bilateral, evenly distributed, and sym-
metrical changes in the hippocampi as postictal hence more likely to
be related to seizure and not the inflammatory process itself. It has
been reported that postictal changes in dogs can be appreciated in
piriform lobes, temporal lobes, hippocampus, and cingulate gyrus and
usually resolve within 16 weeks.26 Therefore, the presence of con-
comitant postictal changes in piriform lobes and cingulate gyri, with
the same MRI signal characteristics of hippocampus, was used as well
to support the classification of hippocampal changes as postictal.
We also recognize that unilateral hippocampal changes could
have been postictal and not necessarily lesion-related. In the present
study, the presence of contrast enhancement and involvement of the
affected hippocampus in the borders of the neighboring lesion were
used to attribute hippocampal MRI abnormality to the lesion itself.
However, not all changes triggered by seizures are reversible. The
most commonly described sequel of acute MRI changes is the develop-
ment of cortical atrophy and gliosis. These permanent changes can lead
to further development of an epileptogenic lesion.41,42 Therefore, the
definitive distinction between postictal and lesion-related changes could
only be established based on the histopathological examination findings.
The role of hippocampus in epileptogenesis is well-known.43 In
humans, mesial temporal lobe epilepsy is the most common form of
refractory epilepsy.44 The pathophysiological hallmark of this specific
epilepsy is sclerosis of the hippocampus. However, the exact mecha-
nisms responsible for the development of epilepsy might differ
depending on the degree of hippocampal sclerosis and underlying eti-
ology.45 An early initial CNS insult can lead to further development of
late-onset of epilepsy,46 or antibody-mediated limbic encephalitis can
be the cause of mesial temporal lobe epilepsy.47
In veterinary medicine, limbic encephalitis with voltage-gated
potassium channel antibodies has been described only in cats.48,49
Considering the lack of subsequent imaging studies, CSF analysis, and
histopathological examination of the brain tissue, it is impossible to
state whether the pathophysiological mechanism of subsequent PEE
in our study was the result of irreversible changes in the brain, partic-
ularly in the hippocampus, temporal and frontal lobes, or caused by
chronic ongoing inflammation.
Median overall survival time of all dogs in this study was 103 weeks.
Dogs with features of increased intracranial pressure, particularly caudal
transtentorial brain herniation and loss of cerebral sulci on MRI, were at
a higher risk of death. Acute symptomatic seizures were not associated
with death in the course of MUO. These results are consistent with
1 report on prognostic factors and outcome using a standard treatment
protocol, which was used for the majority of the cases also in our study.4
However, in the majority of previously published studies, the presence
of seizures was linked to death or poor outcome in dogs with MUO.21-23
The lack of association between ASS and mortality in our study could
arise from differences in inclusion criteria between studies. In order to
include only cases with the inflammatory process, results of CSF analysis
were required for inclusion in the present study. Therefore, we might
have excluded cases with a more severe clinical picture and being at risk
of deterioration following CSF collection.
In previously published studies,4,50-53 the combination of predniso-
lone with cytosine arabinoside improved survival times in dogs with
MUO. In this study, the majority of dogs were also treated with cyto-
sine arabinoside and prednisolone. Treatment with corticosteroids only
was associated neither with mortality in the course of MUO (P = .16)
nor with the development of PEE (P = .66). However, the duration of
the treatment and intervals between cycles varied between individuals.
Therefore, the direct comparison of survival times and risk factors of
PEE between dogs treated with cytosine arabinoside combined with
prednisolone or corticosteroids only was not performed as it could lead
to inaccurate results and limit the study population.
An important aspect of treatment in dogs with MUO and seizures
is treatment with AED. The long-term use of AED is recommended in
case of an identifiable structural brain lesion or history of brain insult.54
The optimum type and duration of AED treatment for patients with
ASS or PEE have not been established in either veterinary or human
medicine.17,28 However, it has been reported in humans that aggressive
control of ASS, particularly SE, plays a crucial role in the prevention of
the development of drug-resistant epilepsy.55 In this study, of 7 dogs
that experienced SE, 3 dogs died within the first 24 hours and 2 devel-
oped PEE. Currently, there are no evidence-based guidelines on the
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choice of AED in veterinary medicine regardless of the cause of epi-
lepsy.54,56 In this study, following initial stabilization, a greater number
of dogs with seizures received phenobarbital followed by levetiracetam.
Approximately 21% of dogs with PEE developed drug-resistant epi-
lepsy; however, the same percentage of dogs required only 1 AED and
28% required 2 AED to control the seizures satisfactorily.
Limitations of the present study include its retrospective nature
and small sample size. Currently, there is no consensus on the definition
of the time period preceding PEE. Definitions vary between studies and
depend mainly on the duration of the follow-up period and AED treat-
ment used.11-16 Therefore, seizures that occur just outside the subjec-
tively defined time period could still be related to an active phase of
the inflammatory process. We decided to follow the most commonly
acknowledged definition from the human literature, and we chose a
7-day cutoff period.5,9,10,29 However, we recognize that this could be
controversial, particularly for 2 cases with PEE which experienced the
first seizure episode 8 and 10 days after diagnosis. Therefore, one could
argue that these 2 cases should be included in the ASS group.
Seizures related to relapse of MUO were classified as provoked
seizures and called reappearing symptomatic seizures. Human medi-
cine guidelines for epidemiologic studies on epileptic unprovoked sei-
zures related to the antecedent conditions are categorized into
2 subgroups: remote symptomatic unprovoked seizures and symp-
tomatic unprovoked seizures. The first category encompasses seizures
related to conditions resulting in a static lesion. The second category
compromises cases with progressive CNS disorders.57 In our study,
the latter category could cover seizures occurring just outside the
window for ASS and reappearing symptomatic seizures.
Furthermore, the lack of standardized long-term treatment proto-
cols with AED could have masked seizure activity potentially leading
to the underestimation of the PEE prevalence. In this study, 5 cases
continued AED treatment until the end of the observation period
despite not showing any seizure activity. How many of these cases
could have experienced seizures remains a matter of speculation.
Moreover, for the majority of cases with seizures, the seizure semiol-
ogy was classified on the basis of the owner's or referring veterinar-
ian's description of the event. Lastly, the histopathological
confirmation was available only for 6 cases which is 1 of the most
common limitations of MUO studies. However, the requirement of
histopathological confirmation of diagnosis would have constituted
survival bias and further limit the study population.
Prospective, multicenter studies are recommended with a larger
number of cases and standardized treatment and investigation proto-
cols to fully determine the risk factors and prevalence of PEE in dogs
with MUO. Moreover, the guidelines for the use of AED need to be
established further.
5 | CONCLUSION
In the present study, half of the dogs with MUO experienced ASS and
almost 1/4th developed PEE. The presence of ASS and hippocampal
lesions on MRI was the strongest predictors of PEE. Dogs with PEE
were younger and had a significantly shorter survival time when com-
pared to dogs without PEE.
This high prevalence of both seizures and epilepsy has significant
implications on the management and prognosis of dogs with MUO, as
it carries the potential to provide an additional burden to an already
unpredictable disease. Although some cases developed drug-resistant
epilepsy, the vast majority (79%) of cases with PEE achieved satisfac-
tory seizure control with AED treatment.
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